Authors
Javeria Fatima, Yasir Hasan Siddique
Published in
Current drug targets. Oct 21, 2026. Epub Oct 21, 2026.
Abstract
Gene therapy has transformed modern biomedical research by enabling curative strategies that target the molecular basis of disease. Among genome-editing technologies, the CRISPR/Cas9 system has emerged as a versatile and efficient platform due to its programmability, simplicity, and precision. This review summarizes the evolution of gene therapy and highlights the therapeutic potential of CRISPR-based genome editing. CRISPR/Cas9 has demonstrated significant potential in correcting disease-causing mutations across multiple inherited disorders, including sickle cell disease, β- thalassemia, familial hypercholesterolemia, phenylketonuria, muscular dystrophies, and cystic fibrosis. Emerging technologies such as base editing and prime editing further improved editing precision and reduced unintended genomic alterations. However, challenges including off-target effects, DNA repair pathway bias, immune responses, and vector-associated toxicities remain major limitations. The review highlights the rapid progress of CRISPR-mediated therapeutics and emphasizes the importance of improving editing accuracy, delivery efficiency, and long-term safety. Advances in vector engineering and genome-editing platforms are expected to overcome current technical and ethical barriers, facilitating broader clinical applications. CRISPR/Cas9 and related genome- editing technologies represent promising disease-modifying and potentially curative therapeutic approaches. Continued optimization of precision, safety, and delivery systems will be essential for successful translation into routine clinical practice.
PMID:
42973349
Bibliographic data and abstract were imported from PubMed on 03 Nov 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 10
- Comments 0